Cassiopeia Olson
About Cassiopeia Olson
Independent director at Atlas Lithium (ATLX) since 2021; attorney specializing in international contracts, securities law, and venture negotiations. Education: B.A. in Economics & Finance (Loyola University Chicago) and J.D. (The John Marshall School of Law). Currently with Mitchell Silberberg & Knupp (since May 2022); previously with Ellenoff Grossman & Schole, Crone Law Group, and Kaplowitz Firm P.C. The Board has determined she is independent under Nasdaq rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Kaplowitz Firm P.C. | Attorney | 2013–2017 | International contracts and venture transactions |
| Crone Law Group | Attorney | 2017–Jan 2020 | Securities law and transactions |
| Ellenoff Grossman & Schole LP | Attorney | Feb 2020–May 2022 | Securities law; venture negotiations |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Mitchell Silberberg & Knupp | Attorney | May 2022–present | Corporate/securities; international transactions |
| Other public company boards | — | — | None disclosed |
Board Governance
- Independence: Olson is one of three independent directors (with Noriega and Petersen) as determined under Nasdaq rules .
- Committees: Audit (member), Compensation (member), Nominations (member); Audit chaired by Stephen R. Petersen, CFA .
- Attendance: In FY2024, Board met/acted 25 times; Audit 8, Compensation 1, Nominations 1. All directors attended at least 75% of Board and committee meetings; all attended the 2024 annual meeting .
- Controlled company: CEO/Chair Marc Fogassa controls ~65.6% of voting power via one Series A preferred share conferring 51% voting rights plus common ownership; company is a “controlled company,” currently not relying on Nasdaq controlled-company exemptions .
- Policies: Insider Trading Policy; Hedging prohibited for directors/officers/employees; Clawback Policy compliant with SEC/Nasdaq Rule 5608 for incentive comp restatements .
Fixed Compensation
| Component | FY 2024 Amount | Notes |
|---|---|---|
| Annual cash retainer | $0 | No director cash fees; program is equity-only |
| Meeting fees | $0 | “No other or additional compensation”; no meeting fees disclosed |
| Committee membership/chair fees | Not disclosed | Not separately specified |
Performance Compensation
| Award Type | Grant Date | Shares/Options | Exercise/Strike | Vesting | Fair Value |
|---|---|---|---|---|---|
| Non-qualified stock options (annual program) | 2024 cycle | 10,000 options | $0.0075 per share | Monthly vest over 1 year | $312,705 (grant-date fair value) |
| Non-qualified stock options (annual program) | Jan 2025 | 10,000 options | $0.0075 per share | Monthly vest over 1 year; cancellable if shareholders don’t approve Proposal 3 | Not disclosed; closing price was $5.28 on Apr 1, 2025 for context |
Performance Metrics: None—director options are time-based, with no performance conditions (monthly vesting; deep in-the-money exercise price relative to market) .
Other Directorships & Interlocks
| Category | Detail |
|---|---|
| Current public company boards | None disclosed |
| Prior public company boards | None disclosed |
| Interlocks with competitors/suppliers/customers | None disclosed |
Expertise & Qualifications
- Securities law, international contracts, venture negotiations; experience with large multinational transactions .
- Education: B.A. Economics/Finance (Loyola University Chicago); J.D. (The John Marshall School of Law) .
- Board service since 2021; multi-committee engagement (Audit, Compensation, Nominations) .
Equity Ownership
| As of Record Date | Direct Common | Options (vested and within 60 days) | Total Beneficial | % of Outstanding | Combined Voting Power |
|---|---|---|---|---|---|
| April 1, 2025 | 1,071 shares | 24,833 shares | 25,905 shares | 0.1% | 0.1% |
Additional context:
- Shares outstanding: 17,498,904 common shares; one Series A preferred share confers 51% of total voting power to Mr. Fogassa .
- Hedging prohibited by policy (alignment-positive) .
- Ownership guidelines for directors: Not disclosed .
Insider Trades and Filing Compliance
| Item | 2024 |
|---|---|
| Late Form 4 filings | 1 (Olson) |
| Late Form 5 filings | 1 (Olson; grant that should have been reported in 2023) |
Note: Company disclosed late filings across multiple insiders; Olson’s late Form 4 and Form 5 are minor compliance lapses but merit monitoring .
Governance Assessment
-
Strengths:
- Independent status; active service on all three key committees (Audit, Compensation, Nominations) .
- Board/committee meeting participation overall strong (≥75% for all directors) .
- Robust governance policies: hedging ban and SEC/Nasdaq-compliant clawback .
- No related-party transactions disclosed involving Olson –.
-
Concerns / RED FLAGS:
- Controlled company dynamics: CEO/Chair holds ~65.6% voting power including Series A preferred conferring 51% voting rights, increasing reliance on board independence and committee rigor .
- Director equity structure: options granted deeply in-the-money (exercise price $0.0075 vs $5.28 market on Apr 1, 2025), which creates guaranteed value and reduces performance sensitivity relative to typical at-the-money grants; monthly vesting without performance metrics .
- Section 16(a) compliance: Olson filed one late Form 4 and one late Form 5 in 2024; monitor filing timeliness .
-
Shareholder feedback signals:
- 2024 say-on-pay for NEOs received ~97% approval; frequency vote favored biennial (~94%)—indicates general investor support for compensation framework (NEOs), though Proposal 3 in 2025 seeks explicit approval of non-employee director compensation for option program continuation .
Implications for board effectiveness and investor confidence:
- Olson’s legal and securities background is well-suited to oversight within Audit, Compensation, and Nominations, supporting process integrity .
- However, the director equity program’s deep ITM option design and lack of performance conditions weaken pay-for-performance alignment and may attract governance scrutiny; investors may prefer RSUs or at-the-money options tied to measurable targets .
- Controlled-company status heightens the need for independent directors to assert robust oversight; Olson’s multi-committee participation is positive, but adherence to filing timeliness must be consistent to maintain governance credibility .
Appendix: Key Committee Assignments
| Committee | Members | Chair | Mandate |
|---|---|---|---|
| Audit | Noriega; Olson; Petersen | Petersen | Financial reporting integrity; auditor oversight; risk and cybersecurity oversight |
| Compensation | Noriega; Olson | Not disclosed | Exec/director comp policies; incentive plans; consultant oversight (no consultant currently retained) |
| Nominations | Olson; Petersen | Not disclosed | Board composition; director nominations; governance guidelines; annual board performance review |